Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2019 August;60(4) > The Journal of Cardiovascular Surgery 2019 August;60(4):433-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  RECENT DEVELOPMENTS IN DES FOR LONG LESIONS 

The Journal of Cardiovascular Surgery 2019 August;60(4):433-8

DOI: 10.23736/S0021-9509.19.10965-2

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Drug-eluting stents for PAD: what does (all) the data tell us?

John PHILLIPS

MidOhio Cardiology and Vascular Consultants, Columbus, OH, USA



When the FDA approved the use of a paclitaxel-coated stent in the peripheral arteries in November of 2012, a new era in the treatment of peripheral arterial disease (PAD) emerged. This marked, for the first time in the United States, that a drug-eluting device was available to treat this complex arterial bed, and has likely changed forever how PAD is treated. Prior to this, US physicians had been using drug-eluting stents (DES) in the coronary arteries for 8 years with exceptional results in both safety and efficacy. Since the Zilver®PTX® (Cook Medical, Bloomington, IN USA) was released, multiple drug-coated balloons (DCB) with paclitaxel have been approved in the US, as has another DES, the Eluvia™ stent (Boston Scientific, Minneapolis, MN USA).


KEY WORDS: Drug-eluting stent; Peripheral arterial disease; Paclitaxel; Femoral artery

top of page